Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Sanguinarine Nitrate
Brand Name
Sanguinarinum Nitricum
Generic Name
Sanguinarine Nitrate
Active Ingredient
SanguinarineCategory
Non-Standardized Food Allergenic Extract [EPC]
Salt Form
Nitrate
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sanguinarinum Nitricum, you must consult a qualified healthcare professional.
Detailed information about Sanguinarinum Nitricum
Sanguinarine is a quaternary benzophenanthridine alkaloid derived from Sanguinaria canadensis. It is primarily classified as a non-standardized plant allergenic extract and has historical use in dental health and topical applications.
Dosage for Sanguinarine is highly dependent on the specific clinical application and the formulation being used. Because it is not a standard systemic medication, there is no universal 'daily dose' for oral consumption.
Sanguinarine is generally not approved for pediatric use. The risk of mucosal irritation and the potential for systemic toxicity make it unsuitable for children. In rare cases where diagnostic allergenic testing is required in a pediatric patient, it must be performed by a board-certified allergist using pediatric-specific dilution protocols.
Specific dosage adjustments for renal impairment have not been established due to the limited systemic absorption of most Sanguinarine formulations. However, in cases of accidental systemic ingestion, patients with a reduced Glomerular Filtration Rate (GFR < 30 mL/min) should be monitored closely for signs of alkaloid toxicity, as renal clearance of metabolites may be delayed.
Because Sanguinarine is metabolized by the liver (specifically via CYP enzymes), patients with significant hepatic dysfunction (Child-Pugh Class B or C) may experience prolonged half-lives of the drug. Use in these populations should be approached with extreme caution, and diagnostic testing should be limited to the smallest effective concentration.
Geriatric patients may have thinner oral mucosa and skin, increasing the risk of local irritation or ulceration. Healthcare providers typically use lower concentrations for diagnostic testing in patients over the age of 65.
Sanguinarine is almost never 'taken' in the traditional sense (swallowed as a pill). Instead, it is administered as follows:
Since Sanguinarine is typically administered in a clinical setting for diagnostic purposes, missed doses are rare. If you miss a scheduled diagnostic appointment, contact your allergist to reschedule. For topical applications, if you miss a dose, apply it as soon as you remember. If it is nearly time for your next application, skip the missed dose and resume your regular schedule. Do not double the amount applied.
Signs of Sanguinarine overdose, particularly from accidental ingestion or excessive topical application, include:
In the event of an overdose, contact emergency services or a poison control center immediately. Treatment is primarily supportive, focusing on airway management and gastric lavage if the ingestion was recent.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or use Sanguinarine-containing products without direct medical guidance.
When used topically or in oral preparations, the most common side effects involve local irritation. These include:
These effects are usually transient and resolve once the substance is removed or the testing period is complete.
Sanguinarine is a potent bioactive alkaloid that must be handled with extreme care. It is not intended for long-term daily use in any form unless specifically directed by a medical specialist. Patients should be aware that many 'natural' or 'herbal' products containing Sanguinaria (Bloodroot) are not regulated for safety or efficacy by the FDA.
No FDA black box warnings for Sanguinarine in its approved allergenic extract forms. However, the historical association with oral leukoplakia serves as a 'de facto' clinical warning for all practitioners.
Sanguinarine should never be used in combination with:
Sanguinarine must NEVER be used in the following circumstances:
Sanguinarine is classified as Pregnancy Category C (or equivalent in modern labeling). There are no adequate and well-controlled studies in pregnant women. Animal studies have suggested that Sanguinaria alkaloids may possess abortifacient (abortion-inducing) properties by stimulating uterine smooth muscle. Therefore, Sanguinarine should be avoided during pregnancy unless the potential benefit to the mother significantly outweighs the potential risk to the fetus. It is especially critical to avoid use during the first trimester when organogenesis (fetal organ development) occurs.
It is not known whether Sanguinarine or its metabolites are excreted in human milk. Because many alkaloids do pass into breast milk and can cause adverse effects in nursing infants (such as gastrointestinal distress or lethargy), breastfeeding is generally not recommended if the mother is receiving systemic or extensive topical treatment with Sanguinarine. A risk-benefit assessment by a pediatrician and a clinical pharmacologist is required.
Safety and effectiveness in pediatric patients have not been established. The use of Sanguinarine in children is generally discouraged due to the heightened sensitivity of pediatric skin and mucosa. If diagnostic testing is absolutely necessary, it must be performed using highly diluted concentrations under the strict supervision of a pediatric allergist.
Sanguinarine is a quaternary benzophenanthridine alkaloid that functions primarily as a potent, non-competitive inhibitor of the Na+/K+-ATPase enzyme. By binding to the alpha-subunit of this pump, Sanguinarine prevents the exchange of sodium and potassium ions across the cell membrane, leading to a loss of membrane potential and eventually cell death. Additionally, Sanguinarine intercalates with DNA, particularly at G-C rich regions, which interferes with DNA replication and transcription. This DNA-binding property contributes to its genotoxic potential and its ability to trigger the p53-mediated apoptotic pathway.
The pharmacodynamic effect of Sanguinarine is characterized by a rapid onset of local irritation. When applied to the skin, the inflammatory response typically peaks within 24 to 48 hours. Its anti-inflammatory effects (via NF-kappaB inhibition) occur at lower concentrations, while its cytotoxic effects dominate at higher concentrations. There is a very narrow therapeutic window between its beneficial anti-microbial properties and its harmful cytotoxic properties.
Common questions about Sanguinarinum Nitricum
Sanguinarine is primarily used today as a diagnostic allergenic extract to identify sensitivities to the Bloodroot plant and related botanical substances. Historically, it was a common ingredient in dental products like toothpastes and mouthwashes to help reduce plaque and gingivitis. However, due to safety concerns regarding oral health, its use in consumer goods has been significantly restricted. In research settings, it is also studied for its potential anti-cancer properties because of its ability to induce cell death in laboratory models. Always consult a healthcare professional before using any product containing this alkaloid.
The most frequent side effects are localized and include redness, stinging, or a burning sensation at the site of application. When used in the mouth, it can cause a metallic taste, dry mouth, and irritation of the gums. More significantly, chronic oral use has been linked to the development of white patches called leukoplakia, which require medical evaluation. Systemic side effects like nausea or dizziness are rare but can occur if the substance is absorbed in large amounts. If you notice persistent irritation or unusual skin changes, contact your doctor immediately.
It is generally advised to avoid alcohol when using Sanguinarine-containing products, especially oral rinses or topical treatments. Alcohol can increase the permeability of the skin and mucous membranes, which may lead to higher-than-intended absorption of the alkaloid. This increased absorption can heighten the risk of local tissue damage or systemic toxicity. Furthermore, alcohol itself can irritate the mouth and skin, potentially worsening any side effects caused by Sanguinarine. Always discuss your lifestyle habits with your healthcare provider when starting a new treatment.
Sanguinarine is generally considered unsafe for use during pregnancy. Animal studies have indicated that alkaloids from the Bloodroot plant can cause uterine contractions, which may increase the risk of miscarriage or preterm labor. There is also a lack of comprehensive human data to confirm that it does not cause developmental harm to the fetus. Because of these risks, healthcare providers typically avoid using Sanguinarine for diagnostic testing or treatment in pregnant women. If you are pregnant or planning to become pregnant, inform your doctor before any procedure involving this substance.
The timeframe for Sanguinarine's effects depends on the intended use. For diagnostic allergenic testing, a reaction (such as redness or a small bump) typically begins to appear within 24 hours, but the final results are usually read by a doctor after 48 to 72 hours. In historical dental applications, anti-plaque effects were generally observed after several weeks of consistent twice-daily use. For its cytotoxic or anti-inflammatory effects in a research context, cellular changes can occur within minutes to hours. Your healthcare provider will give you a specific timeline based on your diagnostic or treatment plan.
Yes, Sanguinarine can generally be stopped suddenly without the risk of withdrawal symptoms, as it is not a physically addictive substance. However, if you are using it as part of a prescribed dermatological regimen or a clinical trial, stopping abruptly may cause your original condition to return or interfere with the study results. If you are experiencing side effects that make you want to stop, it is important to consult your healthcare provider first. They can determine if your symptoms are a normal part of the treatment or if you are having an adverse reaction that requires a different approach.
If you are using a topical Sanguinarine product and miss an application, apply it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed one and continue with your regular routine; do not apply extra product to make up for the missed dose. For diagnostic tests performed in a clinic, a missed 'dose' usually means a missed appointment. In this case, you should call your allergist or doctor immediately to reschedule, as the timing of these tests is critical for an accurate diagnosis. Always follow the specific instructions provided by your medical team.
There is currently no clinical evidence to suggest that Sanguinarine causes weight gain. Because it is typically used topically or in very small diagnostic amounts, it does not have the systemic metabolic effects associated with drugs like steroids or certain antidepressants that are known to affect weight. If you experience unexpected weight changes while using a Sanguinarine-containing product, it is likely due to another underlying medical condition or medication. You should discuss any significant changes in your weight or appetite with your healthcare provider to identify the true cause.
Sanguinarine can interact with several types of medications, particularly those that affect blood clotting or those metabolized by the liver's CYP1A2 enzyme. For example, taking it with anticoagulants like warfarin may increase your risk of bleeding. It may also interfere with the results of other skin tests or the effectiveness of topical corticosteroids. Because of these potential interactions, it is vital to provide your doctor with a complete list of all medications, herbal supplements, and over-the-counter drugs you are currently using. This allows them to safely manage your care and avoid dangerous drug combinations.
Sanguinarine itself is a chemical compound and an alkaloid extract rather than a brand-name pharmaceutical drug in the traditional sense. While it was once sold under brand names like Viadent in the dental market, those specific formulations are now rare. Today, Sanguinarine is available as a generic chemical (often as Sanguinarine Nitrate) for research purposes and as various non-standardized allergenic extracts used by specialists. You will not typically find it as a 'generic' pill at a standard pharmacy. Most Sanguinarine-containing products are specialized medical tools or part of compounded dermatological preparations.
> Warning: Stop using any Sanguinarine-containing product and call your doctor immediately if you experience any of the following:
The primary concern with long-term Sanguinarine exposure is its potential for genotoxicity and carcinogenicity in oral tissues. Chronic irritation of the mucosal lining can lead to cellular changes that may progress to squamous cell carcinoma (a type of skin cancer). This risk is why Sanguinarine was largely removed from the commercial dental market. Additionally, prolonged topical use on the skin can lead to permanent scarring or pigment changes (dyschromia).
Currently, Sanguinarine (as an allergenic extract or chemical allergen) does not carry a formal FDA Black Box Warning. However, the FDA has issued multiple Safety Communications regarding the use of 'black salves' (which contain Sanguinarine/Bloodroot). These warnings emphasize that these products can cause permanent disfigurement, destroy healthy tissue, and lead to the delay of conventional cancer treatments. Patients are strongly advised to avoid any unregulated Sanguinarine products marketed for skin cancer treatment.
Report any unusual symptoms or persistent irritation to your healthcare provider immediately.
For patients undergoing diagnostic testing or specialized treatment with Sanguinarine, the following may be required:
Diagnostic use of Sanguinarine typically does not affect the ability to drive or operate machinery. However, if a patient experiences a systemic reaction, dizziness, or blurred vision during or after a skin test, they should refrain from these activities until symptoms completely resolve.
Alcohol can act as a penetration enhancer for topical substances. Consuming alcohol while using Sanguinarine-containing oral rinses or topical pastes may increase the absorption of the alkaloid into the tissues, potentially heightening the risk of irritation or cellular damage.
There is no known withdrawal syndrome associated with Sanguinarine. However, if you are using it as part of a clinical trial or specialized dermatological regimen, do not stop use abruptly without consulting your provider, as this may affect the results of your treatment or diagnostic process.
> Important: Discuss all your medical conditions, especially any history of skin cancer or oral lesions, with your healthcare provider before starting Sanguinarine.
For each major interaction, the mechanism usually involves either direct competitive inhibition of metabolic enzymes (CYP450) or additive pharmacodynamic effects (such as anti-platelet activity). The clinical consequence is often an increased risk of side effects or a reduction in the therapeutic index of the co-administered drug.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those used for skin or dental health.
Conditions requiring careful risk-benefit analysis include:
Patients allergic to Sanguinarine may also react to related alkaloids such as:
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to botanical extracts, before prescribing or using Sanguinarine.
Clinical studies have not included sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients often have decreased renal and hepatic function, as well as thinner skin (atrophy). This increases the risk of both systemic toxicity and severe local reactions. Dosing for diagnostic purposes in the elderly should be conservative, usually starting at the lowest possible concentration.
In patients with renal impairment, the clearance of Sanguinarine metabolites (like dihydrosanguinarine) may be reduced. While topical use is unlikely to cause issues, any procedure involving systemic absorption should be monitored with serum creatinine and GFR checks. Dose adjustments are typically not required for one-time diagnostic tests but are necessary for repeated exposure.
Patients with hepatic impairment (e.g., cirrhosis, hepatitis) may have a reduced capacity to metabolize Sanguinarine via the CYP450 system. This can lead to elevated plasma levels of the parent alkaloid. Such patients should be monitored for signs of systemic alkaloid toxicity, including hypotension and central nervous system depression.
> Important: Special populations require individualized medical assessment and often require lower concentrations of allergenic extracts.
|---|---|
| Bioavailability | < 10% (Topical/Oral); ~30-50% (Systemic/Animal) |
| Protein Binding | ~90-95% (Primarily Albumin) |
| Half-life | 2.0 - 4.5 hours |
| Tmax | 1.0 - 2.0 hours (post-ingestion) |
| Metabolism | Hepatic (CYP1A1, CYP1A2) |
| Excretion | Biliary/Fecal (>70%), Renal (<20%) |
Sanguinarine is the prototype of the benzophenanthridine alkaloid class. Related compounds include chelerythrine and nitidine. In the context of the FDA's Established Pharmacologic Class (EPC), it is grouped with other allergenic extracts used for diagnostic and therapeutic desensitization.